Tag:
CSC
Latest Headlines
Latest Headlines
Fledgling Verastem outlines investor strategy behind high-risk $50M IPO
As today's report on 2011's small class of biotech IPOs makes clear, this is a lousy time for a drug developer to go public--even if it has a compelling late-stage program to boast about. But
